Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17393996 | 0.89 | L3MBTL1 (0.45) | L3MBTL1ALDH1A1CNR2SMN1; SMN2KMT2A | |
| SCHEMBL2802962 | 0.83 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1CNR2 | |
| SCHEMBL20789189 | 0.81 | MEN1 (0.40) | ALDH1A1SMN1; SMN2KMT2AMAPTMEN1 | |
| SCHEMBL24429434 | 0.81 | ALDH1A1 (0.48) | L3MBTL1ALDH1A1CNR2SMN1; SMN2KMT2A | |
| SCHEMBL24429407 | 0.81 | SMN1; SMN2 (0.50) | L3MBTL1ALDH1A1CNR2SMN1; SMN2KMT2A | |
| SCHEMBL2803101 | 0.79 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1CNR2SMN1; SMN2KMT2A | |
| SCHEMBL22408939 | 0.79 | MMP2 (0.42) | ALDH1A1SMN1; SMN2KMT2AMAPTMAPK1 | |
| SCHEMBL28767740 | 0.78 | CA2 (0.50) | L3MBTL1 | |
| SCHEMBL1604539 | 0.78 | L3MBTL1 (0.46) | L3MBTL1ALDH1A1SMN1; SMN2KMT2AMAPT | |
| SCHEMBL979667 | 0.77 | NOTUM (0.49) | L3MBTL1ALDH1A1SMN1; SMN2KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | ASTRAZENECA AB (SE) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100292279-A1 | Bis-(Sulfonylamino) Derivatives in Therapy | PTGER1, SULT2A1, SULT1E1 | L3MBTL1 2928/4885ALDH1A1 119/4885CNR2 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.